Buongiorno, questa storia ha davvero moltissimo da raccontare a coloro che - decidendo le politiche per commercializzare questi device - dovrebbero avere la pazienza e l'umiltà di... ascoltare L'articolo meriterebbe anche di essere "refactored" per chiarire meglio i diversi "strati" di CDT che tocca :-D Andrea Trentini <andrea.trentini@unimi.it> writes:

... e il cuore mi duole a leggere (io che posso!) questa (https://spectrum.ieee.org/bionic-eye-obsolete) notizia di quella che "noi" (*) etichettiamo con:

- #L3 computing agency rubata e obsolescenza "programmata" (fallisce la ditta)

Leggendo l'articolo mi pare di capire che no, la Second Sight non è mai /tecnicamente/ fallita, sebbene sia praticamente in coma, forse perché era /prodotto/ chiaramente in condizioni di fallimento di mercato: --8<---------------cut here---------------start------------->8--- While the Argus II was technically impressive, it faced financial headwinds. Second Sight was selling the Argus II for around $150,000 in the United States—about five times as much as other neuromodulation devices, according to Greenberg. But even so, he says, the company was losing money: “With all the overhead of sales and regulatory people, it wasn’t profitable.” [...] “The leadership at the time didn’t believe they could make [the Argus] part of the business profitable,” Greenberg says. “I understood the decision, because I think the size of the market turned out to be smaller than we had thought.” --8<---------------cut here---------------end--------------->8--- Dicono: considerando le spese per gli addetti alla vendita e agli affari legali non ci si fa sufficiente profitto Non meno importante: l'efficacia clinica è (stata) dubbia per tutto il periodo della sperimentazione de facto (era stato approvato in EU non si capisce con quale procedura, dalla FDA con una "humanitarian device exception" [1]), quindi considerati costi/benefici non è che tutte le persone affette da quella specifica patologia e completamente cieche ci si sono buttate "a pesce", nonostante il marketing e le pressioni a insabbiare: --8<---------------cut here---------------start------------->8--- [...] Arditi also says that he did a research study including nearly all the U.S. participants in the Argus II clinical trial that showed “weakness” with the device’s vision quality. He says Second Sight wouldn’t let him publish or present the results; the company says it disagreed with his analysis and discouraged him from publishing. [...] Second Sight conducted an FDA-mandated postapproval study of the Argus II, following 30 patients from 2007 to 2019. Over that time, 36 serious and 152 nonserious “adverse events” were observed. The FDA did not make the study’s final report available to Spectrum, and a Freedom of Information Act request filed in May 2021 has yet to be fulfilled. [...] Greenberg’s relationship with Second Sight’s investors had been worsening over the years; he stepped down as CEO in 2015 and then left the board of directors in 2018, a move that he has characterized as a forced departure but that he declined to discuss with Spectrum because of a non disclosure agreement (NDA). [...] However, the letter’s promises were already looking shaky, according to one ex-engineer at the company, who asked not to be named because they had also signed an NDA. “We didn’t really support the basic Argus after that,” the engineer tells Spectrum. “We didn’t sell any more, we didn’t make any more, we didn’t have anything to do with it anymore.” --8<---------------cut here---------------end--------------->8--- Minacce di ritorsini legali, FOIA con tempi di risposta biblici, NDA: Nota: il marketing è ancora lì in bella vista https://secondsight.com/, nonostante la situazione per il prodotto sia ormai disperata

- #L1 lock-in

Aggiungi: - #L4 Transparency Non proprio cristallini, come abbiamo visto sopra. ...per non parlare del consenso informato di quei pazienti che dopo anni hanno detto "se avassi saputo prima non lo avrei fatto". - Lmenouno (o #L-1) ovvero the (analytical) machine Anche le macchine hanno un loro ciclo di vita e per funzionare /devono/ essere manutenute, soprattutto quando sono complesse... e non lo sapranno /mai/ fare da sole, quindi un po' di innovation delusion [3] no? --8<---------------cut here---------------start------------->8--- But in 2013, after four years of regular use, Campbell’s system shut down in the subway station, and despite some repair attempts by Second Sight, never worked again. While she talked with her doctors about having the implant removed, she ultimately decided that the risks of another surgery weren’t worth it. She still has the defunct technology in her left eye. [...] Byland was told about “virtual electrodes,” that is, software upgrades that would boost his system fourfold to around 250 pixels, as well as a new video processing unit. “I was sold,” he says. “I felt like we were on the verge of really making a big breakthrough.” Other Argus II patients Spectrum spoke with were also told they would be getting upgrades, such as a digital camera, thermal imaging, and even facial recognition software. In 2016, a USC professor even raised the possibility of color vision. --8<---------------cut here---------------end--------------->8--- L'illusione è stata talmente pompata ad altissimi livelli che la delusione non può che essere disperante. ...ma non disperiamo, hanno ancora /grandi/ aspettative per questa tecnologia, si tratta solo di fare qualche /aggiustatina/: --8<---------------cut here---------------start------------->8--- an associate professor of ophthalmology at Johns Hopkins University School of Medicine, has set up a network of clinicians who are still working with Argus II patients. The researchers are experimenting with a thermal camera to help users see faces, a stereo camera to filter out the background, and AI-powered object recognition. These upgrades are unlikely to result in commercial hardware today but could help future vision prostheses. --8<---------------cut here---------------end--------------->8--- Il tutto senza aver fatto un minimo di analisi di quanto è stato complicatamente semplice arrivare a questi fallimenti [4], che quindi si ripeteranno /sicuramente/ Un commento all'articolo mi ha colpito: --8<---------------cut here---------------start------------->8--- Lawrence Harris 16 Feb, 2022 Seems these companies need to file documentation in escrow that would allow support of these devices to pass to third parties if they go out of business or choose to abandon the project. This was common in the early days of computer systems. The hospital had such an clause so software support could continue. --8<---------------cut here---------------end--------------->8--- «This was common in the early days of computer systems»: poi cos'è andato "leggermente" storto?!?! :-O [...] Saluti, 380° [1] https://en.wikipedia.org/wiki/Humanitarian_Device_Exemption [2] «Arditi feels that Second Sight promised more than it delivered. “I found it very disturbing that [Second Sight] sold so many of these devices to patients who were relying on hope rather than proven performance.”», scrive l'articolo si Spectrum [3] http://leevinsel.com/the-innovation-delusion [4] c'è ampia letteratura sull'analisi dei rischi ma a me pare che troppi decidano di ignorarla -- 380° (Giovanni Biscuolo public alter ego) «Noi, incompetenti come siamo, non abbiamo alcun titolo per suggerire alcunché» Disinformation flourishes because many people care deeply about injustice but very few check the facts. Ask me about <https://stallmansupport.org>.